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After the completion and refinement of the human genome, the characterization of individual gene products in respect of their functions,
their modifications, their cellular localization and regulation in both space and time has generated an increased demand for antibodies for
their analysis. Taking into account that the human genome contains ¨25,000 genes, and that their products are found in different splice
variants and produce proteins with post-translational modifications, it can be estimated that at least 100,000 different protein products have to
be investigated to gain a complete picture of what’s going on in the proteome of a cell.
Antibodies are preferred tools helping with the characterization and detection of proteins as well as with elucidating their individual
functions. The generation of antibodies to all available human protein products by immunization and/or the hybridoma technology is not only
logistically and financially enduring, but may prove to be a difficult task, as quite a number of interesting targets may evade the immune
response of experimental animals, for example, allosteric variants dependent on fragile interactions to cofactors, highly conserved antigens
etc. For this reason, alternative methods for the generation of antibodies have to supplement these approaches. In vitro methods for antibody
generation are seen to offer this capability. In addition, they may provide a cost effective and large scale production alternative for detection
reagents for the research community in their own right. Among in vitro techniques, phage display has been evolved as the most efficient
option for tackling this problem and approaches optimised for automation are emerging.
Maximum benefit for proteomic research could be generated by judicious and preferably international coordination of the ongoing efforts
to combine the strengths of the well established animal based approaches and the novel opportunities offered by in vitro methods.
D 2005 Elsevier B.V. All rights reserved.Keywords: Proteomics; Phage display; Ligand; Panning1. The challenge of the functional genomics era
The last decade of the 20th century was dominated by the
introduction of high-throughput technologies for genomic
research. The application of robotics for liquid handling,
clone picking and arraying, polymerase chain reaction (PCR)
and DNA sequencing had a tremendous impact on the pace
of data acquisition. As a direct consequence thereof,
sequencing of many prokaryotic and eukaryotic genomes,
including the human genome, has been accomplished
(Lander et al., 2001; Venter et al., 2001) and recently refined0378-1119/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: s.duebel@tu-bs.de (S. Du¨bel).(International Human Genome Sequencing Consortium,
2004), yet many more efforts are on the way.
The genome organisation and the gene content of these
organisms mirror the incredible diversity of nature, from
prokaryotes to eukaryotes. The genotype defines the species
of an organism, the proteome defines the phenotype. By
different interpretations of the same genetic content, dramatic
phenotype variations can be achieved, like those between
caterpillar and butterfly. Therefore, to determine the role of
each gene, tools are needed to investigate the amount,
localization and function of its protein products. Despite
rapid increase of knowledge, around half of the open reading
frames (ORF) identified by bioinformatics tools encode
potential protein products with sequences not related to5) 19 – 29
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tions — not to mention the very large fraction of sequences
with a homology suggesting their function, waiting for
experimental verification. The elucidation of gene function
on a large, genome-wide scale will require systematic
analyses of gene products but in turn provides a link between
the sequence and the phenotype (Blackstock andWeir, 1999).2. Antibodies for functional genomics
The sequencing of the human genome and the accessi-
bility of many of the corresponding gene products and
proteins through large clone collections have given a
significant impetus to the application of molecular-recog-
nition reagents in functional genomics. While this class of
reagents is very diverse, including nucleic acid aptamers,
affinity peptides and artificial binders based on scaffold
molecules (reviewed in: Rimmele, 2003; Ulrich et al., 2004;
Nygren and Skerra, 2004), here, we focus only on anti-
bodies, as they are used in almost all currently ongoing
programs. The use of antibodies will be a valuable asset for
relating function and pathology to genomic sequence in
biology and medicine. These approaches gained signifi-
cance through increasing availability of systematic analy-
tical methods requiring antibodies, for example, protein
expression profiling by high-throughput immunohistochem-
istry (Warford et al., 2004). As a result, there is an intense
interest in applying antibodies to functional genomics and
proteomics, paving the path to a better understanding of
disease processes. Further, antibodies will facilitate the
discovery of new biomarkers and the development of
diagnostic tools for the early detection of diseases.
Once the challenges of high sensitivity and high
throughput are fully met, antibody arrays may allow the
detection of abnormal protein expression profiles in
pathological states and eventually accelerate disease-related
investigations and drug discovery (Cahill, 2001; Hanash,
2003).
2.1. Antibody generation initiatives
As a consequence, several initiatives for the systematic
generation of antibodies are already on the way worldwide.
In a national endeavour, the Swedish Human Proteome
resource (http://www.hpr.se/) is pursuing a program to
generate a protein expression catalogue in different human
tissues and organs. For this purpose, affinity purified
polyclonal sera specific to human gene expression products
are generated. The basic principle of this approach carried
out by Mathias Uhle´n and co-workers is to use Protein
Epitope Signature Tags (PrEST) as antigens. Here, by
utilising bioinformatic tools, protein sequences of 100–150
amino acids with relatively low homology to other proteins
are identified and cloned as fusion proteins for production in
Escherichia coli. The proteins are purified under denaturingconditions and used in mass immunisations. The resulting
polyclonal sera are then affinity purified on individual
PrESTs, yielding monospecific agents in respect of the
antigen, and thereby avoiding polyreactivity problems
frequently observed with polyclonal sera. Finally, the
obtained antibodies are used for immunohistochemistry in
tissue arrays, and the data are integrated to obtain a more
global view on protein expression patterns as, for example,
for all chromosome 21 encoded genes (Agaton et al., 2003,
2004).
In Japan, at the Kazusa DNA Research Institute in Chiba,
Osamu Ohara and co-workers have already generated
approximately 800 polyclonal antibodies against a large
set of proteins in the ROUGE database (Rodent Unidenti-
fied Gene-Encoded Large Proteins; http://www.kazusa.or.jp/
rouge/index.html), derived from ¨1500 mouse counterparts
of human KIAA proteins (mKIAA). The ultimate goal of the
project is to accelerate the elucidation of the functions of
KIAA/mKIAA corresponding gene products in the brain.
All the antibody-derived immunohistological data is col-
lected in a new Integrative Gene and Protein expression
database (InGaP; http://www.kazusa.or.jp/ingap2) where it
is linked with data from gene expression profiles using
cDNA microarrays (Koga et al., 2004a,b).
Furthermore, the Human Proteome Organisation (HUPO;
http://www.hupo.org) has united several animal based anti-
body initiatives in which it wants to generate a large number
of mainly monoclonal antibodies against different human
sub-proteomes such as blood plasma, brain and liver
proteins. Within these different projects the generation of
up to ¨1000 antibodies has been reported (Hanash, 2004).
For example, in the Human Liver Proteome Project (HLPP)
a set of monoclonal antibodies against mitochondrial
proteins will be generated, and in the Human Plasma
Protein Project (HPPP) a monoclonal antibody bank with
currently ¨110 entries has been presented at the HUPO 3rd
Annual World Congress (2004). These projects differ from
the ones mentioned before by following the approach of
identification of these antigens based on their expression
locus and profile. Even a mouse monoclonal antibody bank
covering the entire proteome (EPI) is conceived. Animal
based methods have yielded most of the research antibodies
currently in existence, and are the basis of the majority of
funded programs.
2.2. Limitations and challenges
The ongoing antibody initiatives mentioned above
represent a substantial contribution end encouraging start
towards the systematic analysis of parts of the human
proteome. However, a number of problems still have to be
solved. Most of the antibodies reported by the above
mentioned projects so far result from individual rabbit sera.
Without doubt, quite a number of experiments can be
performed with the amount yielded by one rabbit, but these
sera are not an unlimited resource.
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future is similar to a problem that arose in early stages of the
human genome project. Currently, most of the antibody
programs run on national level and it would be desirable to
coordinate these efforts in the future to obtain antibodies
against as many different gene expression products as
possible. This channelling of efforts will have to be finely
tuned within the collaborating antibody generating initia-
tives and will need to focus on three points: (1) to reduce
work redundancy by ensuring a good information, data and
material flow between participating facilities, (2) to stand
for the delivery of antibodies of standardised quality, and (3)
to introduce and define community standards for efficient
exchange and compatibility of antibody application derived
data. Ongoing initiatives on genome annotation and
proteomics data demonstrate both the power and the
difficulties of such a task. The lesson to be learned for the
antibody generation initiatives is simple: to start as early as
possible with a respective coordination.
A third problem cannot be handled by bioinformatics or
coordination meetings, as it originates in the immune system
itself. All of the aforementioned methods for the generation
of antibodies are expected to fail to provide antibodies to
quite a number of functional proteins. This can be a result of
a number of reasons. First, if the immune system does not
recognise an antigen as immunogenic, no antibodies will be
made (Hayhurst and Georgiou, 2001). This happens for
example to very conserved sequences, and is a particular
problem when monoclonals to mouse proteins are attempted
to be made. With mice being the most widespread
mammalian model both in basic research and in clinical
development, this problem is severe and has to be tackled.
Another type of antigens which usually fails to yield
antibodies in animals are proteins which require a particular
conformation. Usual immunisation procedures, denaturate
proteins, and immunogenicity require the processing into
short peptides, so an allosteric variant resulting from a
fragile cofactor binding easily escapes immunogenicity.
An answer to fill the gap of knowledge for all of these
non-immunogenic antigens is offered by methods which
require neither immunisation nor the processing by an
immune system. These methods, in the following summar-
ised as in vitro methods, solely rely on the mere binding
reaction to select a specific antibody. No antigen processing,
no MHC presentation, no helper cells are needed to yield
specific antibodies, thus releasing the boundaries set by
immunogenicity in animals (Winter and Milstein, 1991).
Antibodies to toxic compounds, lethal pathogens or highly
conserved antigens can be obtained. Further, by controlling
the biochemical milieu during this in vitro antibody
selection, denaturation can be avoided or even allosteric
variants can be induced by adding additional factors during
the very step of selection. A nice example that can be
achieved with these methods is the generation of an
antibody to a conformational variant of a small GTPase
(Nizak et al., 2003).As an extra bonus, in vitro methods allow selection
protocols which can easily be broken down to short
experimental steps with any time of storage between each
step, and which can be handled in the highly parallelised
formats developed within the human genome project. This
qualifies the in vitro methods particularly for upscaling by
the use of automated parallel handling of the selection steps
(Holt et al., 2000a,b; Walter et al., 2001). Further, most
antibodies made in vitro are of human origin, offering the
additional benefit of compatibility to mouse and/or rabbit
antibodies in co-staining/co-localisation experiments.
The caveats and benefits of polyclonal sera and mono-
clonal antibodies, as well as the methods to obtain them,
have been thoroughly discussed and documented during the
last 30 years. In this review, we therefore look onto the
knowledge that has been accumulated on in vitro generation
of antibodies, with particular respect given to the challenges
of producing an antibody depository for proteome research.3. In vitro antibody generation
All the recombinant antibody selection techniques are
based on affinity enrichment and on the simple but extremely
effective concept of linking the phenotype with its genotype,
i.e., linking the protein function with its corresponding gene.
This is best demonstrated by surface display technologies,
such as cell surface display on yeast cells (Feldhaus and
Siegel, 2004), bacteria (Daugherty et al., 1999) and viral
particles — mainly bacteriophage display (Hust and Du¨bel,
2005). However, alternative methods are in use as well
where the DNA and the protein are hold together in vitro
either non-covalently — such as in ribosome display (He et
al., 2004) — or covalently, such as in mRNA display, e.g.,
puromycin-display (reviewed in Lipovsek and Plu¨ckthun,
2004) or the only recently developed covalent antibody
display, where the protein and the corresponding DNA
fragment are covalently fused by the bacteriophage P2
endonuclease P2A (Reiersen et al., 2005).
Nevertheless, among these methods, the most commonly
used selection technology for recombinant antibodies
selection technology until now remains display the M13-
based on filamentous bacteriophage (Fig. 1). In the future,
however, the alternative approaches of generating recombi-
nant antibody molecules may well supplement or replace
these strategies once brought to a comparable maturation
(Bradbury, 2003; Bradbury et al., 2004).
Based on the wealth of experience with antibody phage
display, at least two antibody initiatives have already started to
employ in vitro methods for the systematic generation of
antibodies for proteome research.Within theNational Genome
Research Network of the German Government (http://
www.ngfn.de), the Antibody Factory (http://www.antibody-
factory.de) has very recently started to develop technologies
planned to allow the setup of streamlined processes optimised
to yield recombinant antibodies for proteome research. The
Fig. 1. Phage display allows to isolate antibody fragments by their binding function from large (106–1011) antibody gene fragment repertoires. The biochemical
conditions at the very moment of selection can be exactly controlled. Every antibody clone obtained with this method originates from a single molecular
binding event of an antibody fragment to its antigen. However, its clonal expansion in E. coli provides an indefinite production source for the antibody and
allows its engineering into other formats (whole IgG, enzyme or GFP fusions, diabodies etc.).
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involves the generation of phage display antibody libraries,
new selection procedures on polypropylene supports and
approaches comparing different antigens, like bacterial
expressed proteins or protein segments, as well as oligopep-
tides. Particular focus has been set from the onset to optimise
the resulting products for the needs of the researcher, especially
in respect of the handling by the ‘‘end user’’.
Already more advanced is the FThe Atlas of Gene
Expression_ project in the UK. John McCafferty and
colleagues at the Wellcome Trust Sanger Institute in
Cambridge (http://www.sanger.ac.uk/Teams/Team86/) have
set up a pipeline for the systematic expression profiling of
human proteins by immunohistochemistry and tissue arrays
(Warford et al., 2004). For this purpose, they produce
human protein domains in E. coli and use antibodies
obtained by selections from highly diverse antibody frag-
ment phage display libraries (Dyson et al., 2004).
3.1. Phage display
Both initiatives mentioned above utilises a very similar
method for the selection of the antibodies. They rely onhighly diverse antibody gene repertoires, which can func-
tionally be screened by presenting them on the surface of a
bacterial virus (phage display). Antibody phage display is
based on the groundbreaking work of Smith (1985). Here,
the genotype and phenotype of peptides were linked by
fusing their short gene fragments to the minor coat protein
III gene of the filamentous bacteriophage M13, resulting in
the expression of this fusion protein on the surface of phage
which allowed affinity purification of the gene by peptide
binding. In a similar way, antibody fragments, fused to pIII,
can be presented on the surface of phage M13 (McCafferty
et al., 1990; Barbas et al., 1991; Breitling et al., 1991;
Clackson et al., 1991; Hoogenboom et al., 1991). Regard-
less the production and presentation of complete IgG
molecules (including the Fc part) are not possible due to
limitations of the folding machinery of E. coli, this is not
necessary as the Fv-part of an IgG provides the complete
antigen specificity and can be easily produced in E. coli. For
antibody phage display, two antibody formats are mainly
used: the Fab fragment or the single chain Fv fragment
(scFv). In an scFv, two polypeptides (VH and VL) are
covalently connected via a peptide linker. The dominating
system for the expression of the antibody::pIII fusion
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signal, promoter, resistance marker and phage morphoge-
netic signal, allowing this ‘‘phagemid’’ to be packaged into
assembled phage particles. Helperphage, like M13K07
(Vieira and Messing, 1987) or Hyperphage (Rondot et al.,
2001), are necessary for the production of antibody phage as
they supply the phage proteins not encoded on the
phagemid. Due to a mutated origin, the helperphage genome
is less efficiently packaged into phage than the phagemid,
thus increasing the chances for the selection of the
phagemid of interest during panning. A wealth of different
systems for the display of scFvs or Fabs on filamentous
phage have already been created (for review see Hust and
Du¨bel, 2005).
3.2. Biopanning
The technique of in vitro isolation of specific antibodies
by their binding activity is accurately called ‘‘panning’’,
referring to the gold washers tool used to isolate a tiny
nugget out of a huge pile of rubbish (Parmley and Smith,
1988). Here, the antigen is immobilized on a solid surface,
such as nitrocellulose (Hawlisch et al., 2001), magnetic
beads (Moghaddam et al., 2003), a column matrix (Breitling
et al., 1991) or, currently most widely used, on plastic
surfaces such as polystyrole tubes (Hust et al., 2002) or 96
well polystyrole plates (Barbas et al., 1991). The antibody
phage mixture is incubated with the immobilized antigen,
followed by thorough washing to remove the vast excess of
non-binding antibody phage. The phage bound by their
antibody moiety can subsequently be eluted (for example by
using a protease site between pIII and antibody fragment)
and the released phage re-amplified by infection of E. coli.
This selection cycle can be repeated by infection of the
resulting E. coli colonies with a helperphage to produce new
antibody phage, which then can be used for a new round of
panning (Fig. 1). The number of antigen specific antibodies
is increased with every panning round. The enrichment of
specific antibody clones in each panning round can be
controlled by ‘‘polyclonal ELISAs’’ (Enzyme Linked
Immunosorbant Assay). Usually 2–6 panning rounds are
necessary before individual clones can be isolated.4. Systematic generation of antibodies by phage display
Recombinant antibody technology using combinatorial
libraries and in vitro screening technologies is well suitable
for high-throughput antibody screening on a genome- or
proteome-wide scale (Hallborn and Carlsson, 2002; Hust
and Du¨bel, 2004; Walter et al., 2001). At the moment,
however, proteome-wide applications are still not the major
focus of most recombinant antibody engineering programs
and the libraries and formats available are primarily
optimised for the very different demands of human therapy
(Hust and Du¨bel, 2004). Aiming at very different perform-ance goals, these parameters need adaptation to the different
demands of a streamlined selection process for research
antibodies. Every individual part of the process has to be
reconsidered and optimised. This concerns the antigen
generation methods which have to be designed to match
the throughput (and cost) of the antibody selection process,
the selection of the appropriate antibody format optimised
for the desired application, large-scale selection schemes
and last but not least standardised characterisation and
specificity validation.
4.1. Antigen availability
The availability of high quality target molecules is a
necessary prerequisite for the setup of any successful
antibody generation pipeline. The use of antigens individ-
ually purified from their naı¨ve source is — despite their
preferable superior quality — hardly applicable for paral-
lelised antibody generation. The vast differences of protein
structures and folding requirements, as well as their different
states of modification and activation, render the setup of a
generalised scheme for parallelised recombinant generation
of antigen molecules difficult. Nevertheless, it’s what we
have at the moment. Several human clone collections of
cDNA and full-ORF (open reading frame) expression clones
have been established at non-profit resource centres within
the Human Genome Sequencing Project, e.g., at the MRC
gene service in Cambridge, UK (http://www.hgmp.mrc.
ac.uk/geneservice/index.shtml), the Biological Resource
Centre of the National Institute of Technology and Evalua-
tion in Japan (http://www.nbrc.nite.go.jp/e/hflcdna-e.html),
or the German Resource Centre for Genome Research in
Berlin (http://www.rzpd.de).
4.1.1. Recombinant protein expression from cDNA libraries
Large-scale structural genomics initiatives, for example,
the ‘‘Protein Structure Factory’’ (http://www.proteinstruk
turfabrik.de), have established various supplementary
expression host strategies for the expression of recombinant
protein molecules. A major advantage of using recombinant
selection antigens is the possibility for in-frame fusion to tag
sequences, which facilitate their folding, purification and
their attachment to panning support materials. Oriented
binding is understood as a measure to reduce partial
denaturation and improve epitope accessibility.
Despite undeniable restrictions in it’s capability to make
and/or fold larger eukaryotic proteins, E. coli still is the
most prominent expression host in functional genomics and
proteomics for it’s ease of use and low cost. However, only
¨20% of human proteins can be expressed as soluble
proteins using currently available routine protocols. This
percentage can be somewhat increased by the use of
different tags that promote folding and solubility (Shih et
al., 2002; Scheich et al., 2003). A recent study using 125
mammalian proteins revealed several protein features that
correlated with soluble protein expression, and others that
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and the molecular weight, the number of contiguous
hydrophobic residues and low complexity regions, was
found. There was no relationship between successful
expression and protein pI, grand average of hydropathicity
(GRAVY), or sub-cellular location. Further, the positive
effect of solubility tags was confirmed, with Thioredoxin
(Trx) and maltose binding protein (MBP) leading the list
(Dyson et al., 2004). By allowing denaturation, protein
expression in E. coli is more efficient and, for example,
expression of ¨50,000 individual clones of human proteins
in parallel was achieved based on clone filters (Bu¨ssow et
al., 1998). This arrayed cDNA expression library has
already been used as a resource of proteins for the in vitro
generation of recombinant antibodies (Walter et al., 2001).
Although denatured proteins can be and have been used
as target molecules in vitro antibody selection experiments,
soluble and, hence, more homogenous target structures are
preferred. By using correctly folded antigens, it is feasible to
select antibodies recognizing different epitopes and protein
conformations, which will be of particular value for func-
tional genomic studies. This possibility is a particular
advantage of in vitro generation of recombinant antibodies
when compared to conventional animal immunization
procedures.
Eukaryotic hosts well established for parallelised expres-
sion of recombinant proteins are yeasts. Production proto-
cols in microtitre plates have been developed for
Saccharomyces cereviciae (Holz and Lang, 2004) and in
Pichia pastoris (Bo¨ttner et al., 2002). Despite the glyco-
sylation patterns in yeast are considerably different due to
the presence of high mannose chains, many human proteins
can be obtained as soluble proteins and in a post-transla-
tionally modified form in yeast.
Parallelised production of human proteins also is possible
in insect cells (Albala et al., 2000). For this purpose, the
protein coding genes can be cloned into the baculovirus
system, which permits infection of various insect cell lines.
Shuffling antibody ORF’s from selection to production
systems is facilitated by dual expression vectors allowing
expression in E. coli as well (Chambers et al., 2004).
A significant and powerful option is the use of cell-free
expression systems in which the proteins are expressed in
an in vitro coupled transcription–translation reaction. These
are usually based on either E. coli cell lysates (Kim et al.,
1996), wheat germ cell lysates (Madin et al., 2000) or
reticulocyte cell lysates (Craig et al., 1992), although other
systems based on S. cerevisiae (Tuite et al., 1980) and
Drosophila melanogaster (Scott et al., 1997) have also
been reported. Some of these systems have been optimized
for high-throughput genome-wide applications (Sawasaki et
al., 2002; Busso et al., 2003). For example, the Riken
Structural Genomics Initiative in Japan (http://www.rsgi.
riken.go.jp) produces target proteins almost exclusively in
bacterial cell-free expression systems (Yokoyama, 2003).
Hence, this option is also particularly interesting incombination with recombinant antibody generation by
phage display.
4.1.2. Protein fragments
The aforementioned methods aimed to produce full-
length antigen from every gene, if possible in its naive
conformation, as the use of soluble antigens dramatically
increases the positive outcome of phage antibody selections.
The available data, however, shows that this goal is still out
of reach. By accepting this restriction, many strategies
concentrate on using protein fragments in exchange for a
better throughput. For example, Agaton et al. (2003) have
used bioinformatic tools for the determination of unique
protein epitope signature tags of human proteins, PrEST’s,
and after cloning and expression of the recombinant
molecules with a histidine-tag and an albumin binding
domain, they were purified and used for the immunization
of rabbits. However, although non-expressible protein
regions, like trans-membrane domains, can be omitted, the
success rate for protein expression and purification under
denaturing conditions was 76%. These strategies do not
offer to select for native conformations but still require
protein production and purification efforts similar to those
for antigens generated from full length cDNAs. This can be
avoided in a completely synthetic approach by using
chemically synthesised peptides based purely on bioinfor-
matic analyses of human gene sequences. In this case, sets
of peptides can be predicted to be accessible at the surface
of the protein (Wodak and Janin, 1978). Additional
algorithms may be employed to avoid potential cross-
reactivity to other gene products, to identify epitopes shared
by mouse and man or within gene families etc., finally
resulting in a robotic panning process requiring nothing
more than the input of sequence accession numbers.
Without doubt, not every antibody raised against PrEST’s
or peptides will bind to the naı¨ve form of the protein;
however, countless examples of polyclonal antibodies
generated against peptides in rabbits and mice have been
described and prove the validity of this approach. Further,
unsatisfactory results of the peptide approach observed in
the past may well be alleviated by the possibility of using
large numbers of different peptides for each antigen in a
parallelled panning approach. In addition, the success rate of
epitope prediction may be improved by the generation of
systematic data obtained for the first time in the currently
started parallelised studies. Furthermore, by using, for
example, phosphorylated variants, peptides can facilitate
the search for post-translational modifications. Finally, by
employing peptides synthesised in array formats on solid
phase (Frank, 2002; Frank and Du¨bel, in press) for phage
panning (Bialek et al., 2003), a significant reduction in
numbers of experimental steps may yield an improvement
of throughput that by far exceeds current capabilities.
No matter which antigen source is finally favoured, any
proteome-wide antibody project faces the challenge that the
logistics needed to generate antigens easily equals or
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process itself.
4.2. Phage antibody libraries and formats
Dependent on the source of the antibody repertoire used
for the library generation, the libraries are considered to be
naı¨ve or synthetic, or combinations of both. Naı¨ve libraries
are constructed from light and heavy chain repertoires
isolated from non-immunised donors. For example, naı¨ve
libraries consisting of the repertoire of human IgM genes
isolated from peripheral blood lymphocytes (PBL) (Marks et
al., 1991; Do¨rsam et al., 1997) and from bone marrow or
tonsils (Vaughan et al., 1996) have been constructed. (Semi-)
synthetic libraries can be derived from unrearranged anti-
body genes of germline cells by cloning the CDR-contain-
ing gene segments of the different heavy and light chain
families and rearrangement in vitro by PCR (e.g. Hoogen-
boom and Winter, 1992; Nissim et al., 1994). Other (semi-
)synthetic libraries have Ftargeted_ diversity and consist
solely of one or a few VH and VL frameworks and contain
partially randomised CDR’s. The diversity is introduced by
PCRs with DNA–oligonucleotides having degenerated
codons at desired positions. This procedure has the
advantage that variations are only allowed in positions
essential for antigen binding and by choosing well-
expressed and well-folding frameworks (Pini et al., 1998;
Knappik et al., 2000; So¨derlind et al., 2000). Both naı¨ve and
semi-synthetic antibody libraries have yielded antibodies
with KD’s down to the sub-nanomolar range, so both types
of libraries – or combinations thereof – can be considered
as sources for the selection of antibodies for functional
genomics.
Most of the human naı¨ve libraries have been assembled
to yield antibody fragments in the scFv format, however,
there are also large naı¨ve antibody phage display libraries
made in the Fab format (De Haardt et al., 1999). ScFv-
fragments are constructed by connecting the variable
domains of the heavy and the light chains (VH and VL)
by an amino acid linker of appropriate length (12–25
residues). ScFv’s are small and usually well presented on the
phage surface. A potential disadvantage is their lack of a
structural support for VH–VL associations. As the VH–VL
dissociation constants are within the low micro- and
medium nanomolar range, their integrity is relying on the
Fkinetic_ stabilisation by the linker (Glockshuber et al.,
1990), which does not prevent VH–VL dissociation but
massively promotes re-association, thus rendering many
scFv’s susceptible to aggregation at higher concentrations.
Fab fragments are comprised of the variable domain (VH)
and the CH1 domain of the heavy chain and the complete
light chain (CL). The stability of Fab fragments is
comparable to IgG due a to natural disulphide bond
covalently linking the two chains, and the additional
contribution of CL–CH1 association. However, the pre-
sentation of Fab fragments on the surface of phage particlesis usually not as efficient as for scFvs due to the necessity to
produce and combine two polypeptides. However, from the
viewpoint of a proteomic researcher, when compared to
scFv’s, Fab fragments offer the advantage not only to be
more stable, but also to be more compatible to currently
used assays without major adaptations to the protocol. They
contain the entire light chain and a part of the constant
region of an IgG heavy chain, so the standard secondary
sera used for IgG detection can recognise them, while the
detection of scFv requires specialised protocols usually
employing additional anti-tag antibodies, a restriction
applying as well to the multitude of alternative scaffolds
for binding molecules, like anticalins, fibronectins, leucine-
rich repeat proteins or ProteinA, among others.
4.3. Large scale selection schemes
There are various strategies for target presentation:
proteins can be attached to microtitre plate surfaces (Krebs
et al., 2001), to magnetic beads (e.g. by specific expression-
tag sequences, Walter et al., 2001) or to immunopins in the
96-well format (Lou et al., 2001). They can be prepared by
blotting 2D gels onto membranes (Liu and Marks, 2000; Liu
et al., 2002), or represented by short oligopeptides
(Hultschig and Frank, 2004). However, not all approaches
are amenable for parallel selection and automation. For
instance, selection efficacy on immunopins is limited by the
rather small surface available for antigen presentation and
lack of automation capability. Blotted 2D gels are spatially
difficult to reproduce and the protein concentrations and
modifications can strongly vary.
In the following, we focus on approaches proven in
respect of automation. Countless immunological assays are
based on microtitre plates and, hence, automation instru-
ments for this format are commercially available. The setups
can comprise individual liquid handling robots, ELISA
washers, incubators and spectrophotometers. They are also
amenable to phage display selections (Krebs et al., 2001).
Alternatively, antigens can be coated onto magnetic
particles by using an automated pin-based magnetic particle
processor (Kingfisher). Here, selections or ELISA can be
handled in the 96-well plate format as well. The processor
allows several positions for accommodating microtitre
plates pre-filled with solutions for washing or incubation
steps. Steps are performed by movement of the beads from
plate to plate (Rhyner et al., 2003). An advantage of this
approach is reduced background binding, as due to moving
the beads, there are no remaining liquids in the system
(Konthur and Walter, 2002). Further, problems arising from
Fleaky_ liquid handling systems can be avoided, not to
mention the considerable cost savings by significantly
reduced numbers of pipetting tips required in the process.
A new approach uses peptide arrays for phage display
selections (Frank, 2002; Bialek et al., 2003). A significant
advantage of this system would be that large numbers of
different antigen peptides are directly synthesised in parallel
Z. Konthur et al. / Gene 364 (2005) 19–2926on the polypropylene folies, which are an appropriate
support matrix for phage selections. Arrays of up to 2000
independent peptides have already been made, but their
integration into an in vitro antibody generation pipeline still
has to be implemented. New methods which may further
facilitate antigen logistics are constantly emerging, for
example, the in vitro synthesis of proteins from DNA
spotted on arrays (PISA, He and Taussig, 2001), but have
not yet been employed for antibody selections.
4.4. Characterisation of in vitro selected antibodies
The problem of ‘‘high-throughput’’ specificity validation
of antibodies applies to both animal based and in vitro
methods in a very similar way. Ideally, the antigen used for
immunisation or panning should not be used for specificity
conformation to prevent circle conclusions, which may, for
example, hide the artefact of an antibody binding to a
contaminant. However, in any application targeting system-
atic antibody generation in a proteomic scale, this cannot be
achieved routinely, and a compromise has to be found.
Current large-scale strategies for the screening of enriched
phage display libraries are based on the concept of the
arrayed library (Lennon and Lehrach, 1991). Using picking
and spotting technology (Eickhoff et al., 2002), thousands
of antibody-producing clones can be picked and gridded on
membranes as bacterial clone arrays, and screened for
specific binding with labelled selection targets (De Wildt et
al., 2000). Most commonly, however, single colonies are
picked into 96- or 384-well microtitre plates to generate
antibody phage producing monoclonal cultures, and sub-
sequent test of antibody specificity is done by enzyme
linked immunosorbant assay (ELISA) on solid phase
immobilised selection targets. This method is well adapted
to the automated equipment pipelines of liquid handling
robots, plate-washers and spectrophotometers. Modularised
automated solutions have been developed for downstream
evaluation of antibody selections. One station is comprised
of a picking robot to generate single antibody expressing
clones, another station is concerned with the antibody
fragment production from bacterial cultures (100 microtitre
plates in parallel; Hallborn and Carlsson, 2002). A large
spectrum of variant methods has been developed for ELISA
based specificity confirmation, including detection of
soluble pIII::antibody protein (Mersmann et al., 1998) or
even subcloning as fusion to alkaline phosphatase (Han et
al., 2004), among many others. However, for a streamlined
parallel application, addition of steps is always critical. A
convenient way to confirm the binding of selected antibody
fragments independent from the phage background is the
use of the supE system, which allows to switch from pIII-
fusion to free antibody fragment (Griffiths et al., 1993).
Parallelised ELISA has been demonstrated for 10.000
clones/day (Hallborn and Carlsson, 2002).
While microtitre plate-based ELISA screening allows 96
to 384 wells per plate, the use of protein microarrays allowsan even higher throughput. The microarray-chip based
method MIST (Multiple Spotting Technique, Angenendt et
al., 2003) screens up to ¨10,000 interactions at a time on a
single chip, allowing parallel chessboard analysis of differ-
ent antibody fragments for binding to different antigens, as
well as to numerous negative control proteins. Here, the
targets and the negative control proteins are spotted on a
glass chip first. Then, after blocking, the antibody fragments
are spotted on top of the first spots and detected with a
secondary antibody (Angenendt et al., 2004). Similarly,
selected recombinant antibodies can be screened for mono-
specificity on recombinant protein micro- and macroarrays
(Lu¨king et al., 1999; Holt et al., 2000b). With increasing
numbers of protein arrays available, and by using an
intelligent selection of ‘‘non-binding’’ antigens comprising
closely related proteins as well as possible contaminants,
parallelised antibody validation may offer a significant
decrease of ‘‘false positives’’. Individual specifically binding
antibody fragments can also be subjected to kinetic analyses
and affinity determination. This can be done for example by
parallelised surface plasmon resonance in 96-well format
equipment (for review see Malmqvist, 1999).
The selected antibody fragments can further be analysed
on tissue microarrays, and automated setup for this were
already reported (Warford et al., 2004). However, a true
control of specificity has to employ two variants of every
antigen. A solution which already could be achieved in
automated form combines cDNA derived protein and
synthetic peptides, with one used for panning, the other
for specificity confirmation, or vice versa. It is however
evident that careful control of the specificity of individual
antibody preparations remains in the responsibility of the
end user, as a true automated solution has yet to be
established.5. Conclusions and outlook
With the increasing awareness that many questions in the
field of life sciences can only be answered by looking at
multitudes of parameters at a time, there is also a growing
demand for multinational resources and infrastructures,
which can provide the research community with biological
tools. In the case of antibodies, such an initiative offers
significant benefits. For instance, it can pool all available
data from the rapidly maturing national antibody initiatives,
thus very much speeding up broad and systematic applica-
tions of the research agents by providing faster availability
of both antibodies and research results. In contrast to other
proteome related data, antibodies have the advantage of
being established as robust research reagents for a long time,
they have an easily to define small set of critical parameters
and a good track record of standardization. As a result,
dissemination and utilisation of knowledge and research
agents can be expected to be much faster and more
successful than with most of the other materials generated
Z. Konthur et al. / Gene 364 (2005) 19–29 27or ‘‘standardised’’ in combined proteomics efforts. Further,
by defining common future goals and monitoring and
distributing the workload between international participants,
redundancy is prevented and maximum benefit is generated
from the national financial resources.
We believe that by combining the already existing well
established methods plus optimizing the application of in
vitro methods for the needs of proteomics, antibodies will
have a major impact on the progress of functional genomics
without being too demanding on another Fomics_ matter —
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